Literature DB >> 7772063

Identification of a new apolipoprotein E variant (E2 Arg142-->Leu) in type III hyperlipidemia.

P Richard1, M P de Zulueta, I Beucler, J L De Gennes, A Cassaigne, A Iron.   

Abstract

A new rare apolipoprotein E mutant was identified as we were investigating the apolipoprotein E genotype of patients with type III hyperlipidemia (HLP III). The unusual DNA restriction fragment length polymorphism profile and then the sequence analysis of a PCR amplified fragment of the proband's apo E gene revealed a simple base substitution (G-->T) at nucleotide 3836. This mutation leads to the replacement of arginine by leucine at position 142 of the mature protein. The proband carried the mutant allele at the heterozygous status with an epsilon 3 allele. Subsequently, analysis of the proband's father's apo E gene showed that same mutated allele associated with an epsilon 2 allele. The two subjects presented a dysbetalipoproteinemia in which this new apo E variant could be implicated.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7772063     DOI: 10.1016/0021-9150(94)05393-w

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  3 in total

Review 1.  The key role of apolipoprotein E in atherosclerosis.

Authors:  Kirsty Greenow; Nigel J Pearce; Dipak P Ramji
Journal:  J Mol Med (Berl)       Date:  2005-04-13       Impact factor: 4.599

Review 2.  Establishing the relationship between familial dysbetalipoproteinemia and genetic variants in the APOE gene.

Authors:  Britt E Heidemann; Charlotte Koopal; Alexis Baass; Joep C Defesche; Linda Zuurbier; Monique T Mulder; Jeanine E Roeters van Lennep; Niels P Riksen; Christopher Boot; A David Marais; Frank L J Visseren
Journal:  Clin Genet       Date:  2022-08-22       Impact factor: 4.296

Review 3.  Role of apolipoprotein E in neurodegenerative diseases.

Authors:  Vo Van Giau; Eva Bagyinszky; Seong Soo A An; Sang Yun Kim
Journal:  Neuropsychiatr Dis Treat       Date:  2015-07-16       Impact factor: 2.570

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.